drugset / Trial / NCT01468155
DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation
Phase 4
Completed
50 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Boehringer Ingelheim · collab
NaSingle-groupOpen-labelTreatment
Summary
It is hypothesized that peri-ablation Dabigatran will be a safe and effective method of peri-procedural anticoagulation for Atrial Fibrillation (AF) ablation, resulting in a low rate of peri-procedural bleeding and thromboembolic complications.
Timeline
- Start
- 2011-07-13
- Primary completion
- 2017-01
- Completion
- 2017-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dabigatran | Unknown | 110 mg | — |
| Comparator | Dabigatran | Unknown | 150 mg | — |